Tenaya reports Q4 net loss $29.9M; cash $104.6M; TN-201 data and TN-401 dosing expected H2 2024

Tenaya Therapeutics, Inc.

Net loss $29.9M ($0.40/sh) Q4 2023; full year net loss $124.1M ($1.68/sh).
Cash, equivalents and investments $104.6M at Dec 31, 2023; Feb 2024 financing adds $46.5M net, extending runway into H2 2025.
Initial safety and biomarker data from MyPeak-1 Phase 1b of TN-201 for MYBPC3 HCM expected H2 2024; first patient dosed Oct 2023.
RIDGE-1 Phase 1b of TN-401 for PKP2 ARVC on track to dose first patient H2 2024; FDA Fast Track granted Nov 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tenaya Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, n, EPS $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or.

Period: the fourth quarter and full year ended December 31, 2023
Net income: Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, n
EPS: $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or
Result: reported results

Exact text from the filing

Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023. For the full year 2023, net loss was $124.1 million, or $1.68 per share.

View on SEC.gov

Browse all earnings releases →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-032826

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.